ArticleIET nanobiotechnology2019
Human blood test based on surface-enhanced Raman spectroscopy technology using different excitation light for nasopharyngeal cancer detection.
Article in IET nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 10 citations in OpenAlex.
- KYNU is a potential metabolic-related biomarker for nasopharyngeal carcinoma by Raman spectroscopy, metabolomics, and transcriptomics analysis.Discover oncology · 2025Article
- Quantification of Antiretroviral Drug Emtricitabine in Human Plasma by Surface Enhanced Raman Spectroscopy.ACS omega · 2025Article
- Mammalian cell and tissue imaging using Raman and coherent Raman microscopy.Wiley interdisciplinary reviews. Systems biology and medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC), a kind of squamous cell carcinoma, occurs in the top and the side wall of nasopharyngeal, which harms human health and life. In this study, a novel blood test (SERS) was carried out for 30 NPC patients and 30 normal ones. Using multi-variate statistical analysis for spectral data, the diagnostic sensitivities of 89.3% (50/56) and 85.7% (48/56) can be achieved for 633 and 785 nm exciting wavelength, respectively. Also corresponding specificities are 71.4% (41/56) and 78.6% (44/56), respectively. These results demonstrated that the two kinds of excitation wavelength all have the feasibility of obtaining high-quality SERS spectra to differentiate cancer from normal samples. Furthermore, the performance of the SERS test with 785 nm wavelength excitation is nearly equal to the SERS experimental effect under 633 nm wavelength excitation for NPC detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.